NYSE:JNJPharmaceuticals
Johnson And Johnson Balances Myeloma Win With Tracleer Antitrust Costs
Johnson & Johnson (NYSE:JNJ) received FDA approval for TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO as a treatment option for relapsed or refractory multiple myeloma as early as second line.
The new regimen targets patients with high unmet medical need and is positioned as a potential new standard of care versus existing treatment approaches.
Separately, Johnson & Johnson agreed to pay $65 million to settle an antitrust class action related to alleged delayed generic competition for...